0000950170-24-030779.txt : 20240313 0000950170-24-030779.hdr.sgml : 20240313 20240313161509 ACCESSION NUMBER: 0000950170-24-030779 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240308 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240313 DATE AS OF CHANGE: 20240313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Outset Medical, Inc. CENTRAL INDEX KEY: 0001484612 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 200514392 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39513 FILM NUMBER: 24746080 BUSINESS ADDRESS: STREET 1: 3052 ORCHARD DRIVE CITY: SAN JOSE STATE: CA ZIP: 95134 BUSINESS PHONE: 669-231-8200 MAIL ADDRESS: STREET 1: 3052 ORCHARD DRIVE CITY: SAN JOSE STATE: CA ZIP: 95134 FORMER COMPANY: FORMER CONFORMED NAME: Home Dialysis Plus, Ltd. DATE OF NAME CHANGE: 20100219 8-K 1 om-20240308.htm 8-K 8-K
0001484612false00014846122024-03-082024-03-08

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 8, 2024

Outset Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-39513

20-0514392

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

3052 Orchard Dr.,

San Jose, California

95134

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (669) 231-8200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

OM

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Director

On March 8, 2024, Catherine Szyman, a member of the Board of Directors (the “Board”) of Outset Medical, Inc. (the “Company”), resigned from the Board in preparation for her pending role as Chief Executive Officer of Edwards Lifesciences’ Critical Care spinoff, with such resignation effective March 12, 2024. Ms. Szyman’s resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Appointment of Director

On March 10, 2024, the Board appointed Brent D. Lang as a new member of the Board and as a member of the Audit Committee of the Board, with such appointment effective March 12, 2024.

Mr. Lang fills the vacancy created by the resignation of Ms. Szyman and his term of office as a class III director will expire at the Company’s 2026 annual meeting of stockholders or until his successor has been elected and qualified or his earlier death, resignation or removal. The Board has determined that Mr. Lang is an “independent director” as defined under the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and the listing requirements and rules of the Nasdaq stock market.

Mr. Lang previously served as President and Chief Executive Officer, and on the board of directors, of Vocera Communications, Inc. (“Vocera”), a global provider of clinical communication and workflow solutions, from June 2013, and as Chairman of the board of directors from June 2018, until February 2022 when the company was acquired by Stryker Corporation (“Stryker”), a multinational medical technology corporation. Prior to being named CEO, Mr. Lang held various leadership positions at Vocera beginning in 2001, including as its President and Chief Operating Officer. His experience previous to Vocera includes leadership roles at 3Com Corporation and strategy consulting at Monitor Company, Inc. Mr. Lang holds a B.S. from the University of Michigan and an M.B.A. from the Stanford University Graduate School of Business.

Mr. Lang will be compensated in a manner consistent with the Company’s other non-employee directors, as described under the heading “Non-Employee Director Compensation Policy” in the Company’s definitive proxy statement filed with the SEC on April 13, 2023. Mr. Lang will also enter into the Company’s standard director and officer indemnification agreement, the form of which was previously filed by the Company as Exhibit 10.1 to Amendment No. 1 to the Company’s Registration Statement on Form S-1/A (Registration No. 333-248225), filed with the SEC on September 9, 2020. There are no arrangements or understandings between Mr. Lang and any other persons pursuant to which he was appointed as a director. Furthermore, there are no transactions in which Mr. Lang has an interest that would be required to be reported under Item 404(a) of Regulation S-K.

Item 7.01. Regulation FD Disclosure.

On March 13, 2024, the Company issued a press release announcing the resignation of Ms. Szyman and the appointment of Mr. Lang. A copy of the press release is attached hereto as Exhibit 99.1.

The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

Description

99.1

Press Release entitled “Outset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors” dated March 13, 2024

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Outset Medical, Inc.

 

Date: March 13, 2024

By:

/s/Nabeel Ahmed

Nabeel Ahmed

Chief Financial Officer

 

 

 EX-99.1 2 om-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

 

Outset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors

San Jose, CA March 13, 2024 – Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of medical technology veteran Brent D. Lang to its board of directors. Mr. Lang most recently served as Chairman and Chief Executive Officer of Vocera Communications, a global provider of clinical communication and workflow solutions, until its acquisition by Stryker for $3 billion in 2022.

“Brent brings a wealth of healthcare expertise to the Outset board, including in growing and scaling software-enabled business models, which is well-aligned with our recurring revenue model,” said Leslie Trigg, Chair and Chief Executive Officer. “He is an ideal board member to help guide our continued growth and with a vision to improve the lives of patients that fits perfectly with Outset’s moral mission.”

Concurrent with Mr. Lang’s appointment, Katie M. Szyman has stepped down from the Outset board in preparation for her pending role as Chief Executive Officer of Edwards Lifesciences’ Critical Care spinoff.

“As we welcome Brent, we want to also thank Katie for her service to the Outset board during a period of growth and change following our public offering,” added Ms. Trigg. “We wish her well as she begins an exciting new phase of her career journey.”

Mr. Lang will serve on the Audit Committee of the Outset board. He is Chairman of the Movella Holdings Inc. board, a company specializing in movement digitization, and a member of the Thriveworks board, a private company that provides mental health services. Including his role as Chairman and CEO, Mr. Lang spent more than 20 years in various leadership positions at Vocera, including President and Chief Operating Officer and Vice President of Marketing and Business Development. Earlier in his career, he held various roles at 3Com Corporation, a networking company, and worked as a strategy consultant for Monitor Company, Inc., a consulting firm advising Fortune 500 companies. Mr. Lang holds a B.S. from the University of Michigan and an M.B.A. from the Stanford University Graduate School of Business. He was also a gold medalist member of the 1988 U.S. Olympic swimming team.

“I look forward to joining such an accomplished board, and a company that is having a direct and profound impact on the lives of dialysis patients and providers,” said Mr. Lang. “The Outset team has surrounded its innovative Tablo platform with a highly differentiated software and service ecosystem that provide clear opportunities for growth well into the future.”

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

Contact

Jim Mazzola

Investor Relations

jmazzola@outsetmedical.com

 

 

 EX-101.SCH 3 om-20240308.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Pre-commencement Issuer Tender Offer Entity Address, State or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Entity Ex Transition Period Entity Ex Transition Period Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre-commencement Tender Offer Cover [Abstract] Cover Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Securities Act File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Title of 12(b) Security Document Type Document Type Document Type XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Mar. 08, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 08, 2024
Entity File Number 001-39513
Entity Registrant Name Outset Medical, Inc.
Entity Central Index Key 0001484612
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-0514392
Entity Address, Address Line One 3052 Orchard Dr.
Entity Address, City or Town San Jose
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95134
City Area Code 669
Local Phone Number 231-8200
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol OM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports om-20240308.htm om-20240308.xsd http://xbrl.sec.gov/dei/2023 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "om-20240308.htm": { "nsprefix": "om", "nsuri": "http://www.outsetmedical.com/20240308", "dts": { "inline": { "local": [ "om-20240308.htm" ] }, "schema": { "local": [ "om-20240308.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_4d8fa147-8ad2-40a6-bec5-9e806644c5de", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "om-20240308.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4d8fa147-8ad2-40a6-bec5-9e806644c5de", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "om-20240308.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "verboseLabel": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.outsetmedical.com/20240308/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0000950170-24-030779-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-030779-xbrl.zip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�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end XML 14 om-20240308_htm.xml IDEA: XBRL DOCUMENT 0001484612 2024-03-08 2024-03-08 0001484612 false 8-K 2024-03-08 Outset Medical, Inc. DE 001-39513 20-0514392 3052 Orchard Dr. San Jose CA 95134 669 231-8200 false false false false Common Stock, $0.001 par value per share OM NASDAQ false